Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases

Cancer Letters

Volumn 314, Issue 2, 2012, Pages 176-184

  Hussein, Osama ^a,c   Tiedemann, Kerstin ^a   Murshed, Monzur ^a,b   Komarova, Svetlana V ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Bone metastases; Breast cancer; mTOR; Osteoclast; Rapamycin

Indexed keywords

RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE METASTASIS; BREAST CARCINOMA; CANCER SURVIVAL; CARCINOMA CELL; CELL POPULATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; METASTASIS POTENTIAL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RAT; TIBIA; TREATMENT RESPONSE; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; CELL CULTURE; DRUG EFFECT; EXPERIMENTAL NEOPLASM; METASTASIS; MOUSE; OSTEOBLAST; PATHOLOGY; PHYSIOLOGY;

MUS;

ANIMALS; BONE NEOPLASMS; CELLS, CULTURED; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS; SIROLIMUS;

EID: 84855717694     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.026     Document Type: Article

References (56)

1. K.R. Hess, G.R. Varadhachary, S.H. Taylor, W. Wei, M.N. Raber, R. Lenzi, J.L. Abbruzzese, Metastatic patterns in adenocarcinoma, Cancer 106 (2006) 1624-1633
2. T. Hamaoka, J.E. Madewell, D.A. Podoloff, G.N. Hortobagyi, N.T. Ueno, Bone imaging in metastatic breast cancer, J. Clin. Oncol. 22 (2004) 2942-2953.
3. G.N. Hortobagyi, R.L. Theriault, A. Lipton, L. Porter, D. Blayney, C. Sinoff, H. Wheeler, J.F. Simeone, J.J. Seaman, R.D. Knight, M. Heffernan, K. Mellars, D.J. Reitsma, Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: Protocol 19 Aredia Breast Cancer Study Group, J. Clin. Oncol. 16 (1998) 2038-2044
4. M. Kerba, J.S. Wu, Q. Duan, N.A. Hagen, M.I. Bennett, Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy, J. Clin. Oncol. 28 (2010) 4892-4897.
5. R.E. Coleman, R.D. Rubens, The clinical course of bone metastases from breast cancer, Br. J. Cancer 55 (1987) 61-66.
6. M. Bendre, D. Gaddy, R.W. Nicholas, L.J. Suva, Breast cancer metastasis to bone: it is not all about PTHrP, Clin. Orthop. Relat. Res. (2003) S39-45
7. T.A. Guise, K.S. Mohammad, G. Clines, E.G. Stebbins, D.H. Wong, L.S. Higgins, R. Vessella, E. Corey, S. Padalecki, L. Suva, J.M. Chirgwin, Basic mechanisms responsible for osteolytic and osteoblastic bone metastases, Clin. Cancer Res. 12 (2006) 6213s-6216s
8. .M. Kinder, E. Chislock, K.M. Bussard, L. Shuman, A.M. Mastro, Metastatic breast cancer induces an osteoblast inflammatory response, Exp. Cell Res. 314 (2008) 173-183
9. J.E. Fong, D. Le Nihouannen, S.V. Komarova, Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of g-secretase, J. Biol. Chem. 285 (2010) 31427-31434.
10. J.R. Berenson, L. Rajdev, M. Broder, Pathophysiology of bone metastases, Cancer Biol. Ther. 5 (2006) 1078-1081.
11. Y.C. Chen, D.M. Sosnoski, U.H. Gandhi, L.J. Novinger, K.S. Prabhu, A.M. Mastro, Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer, Carcinogenesis 30 (2009) 1941-1948.
12. H. Morgan, A. Tumber, P.A. Hill, Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor, Int. J. Cancer 109 (2004) 653-660.
13. Y. Guo, K. Tiedemann, J.A. Khalil, C. Russo, P.M. Siegel, S.V. Komarova, Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation, Bone 43 (2008) 386-393.
14. K. Tiedemann, O. Hussein, G. Sadvakassova, Y. Guo, P.M. Siegel, S.V. Komarova, Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways, J. Biol. Chem. 284 (2009) 33662-33670.
15. J.M. Chirgwin, T.A. Guise, Molecular mechanisms of tumor-bone interactions in osteolytic metastases, Crit. Rev. Eukaryot. Gene Expr. 10 (2000) 159-178.
16. S. Beslija, J. Bonneterre, H.J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W.J. Kostler, M. Krainer, S. Menard, T. Petit, L. Petruzelka, K. Possinger, P. Schmid, E. Stadtmauer, M. Stockler, B.S. Van, C. Vogel, N. Wilcken, C. Wiltschke, C.C. Zielinski, H. Zwierzina, Third consensus on medical treatment of metastatic breast cancer, Ann. Oncol. 20 (2009) 1771-1785.
17. F. Cardoso, M. Castiglione, Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up, Ann. Oncol. 20 (Suppl. 4) (2009) 15-18.
18. A. Lipton, R. Cook, F. Saad, P. Major, P. Garnero, E. Terpos, J.E. Brown, R.E. Coleman, Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid, Cancer 113 (2008) 193-201.
19. A. Lipton, R.J. Cook, P. Major, M.R. Smith, R.E. Coleman, Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity, Oncologist 12 (2007) 1035-1043.
20. O. Hussein, K. Tiedemann, S.V. Komarova, Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis, Bone 48 (2011) 202-211.
21. A. Lipton, G.G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J.J. Body, B.R. de, R. Berardi, P. Gascon, K.S. Tonkin, R.E. Coleman, A.H. Paterson, G.M. Gao, A.C. Kinsey, M.C. Peterson, S. Jun, Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy, Clin. Cancer Res. 14 (2008) 6690-6696.
22. T. Sugatani, K.A. Hruska, Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors, J Biol Chem 280 (2005) 3583-3589.
23. H. Glantschnig, J.E. Fisher, G. Wesolowski, G.A. Rodan, A.A. Reszka, M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase, Cell Death Differ. 10 (2003) 1165-1177.
24. E. Luegmayr, H. Glantschnig, G.A. Wesolowski, M.A. Gentile, J.E. Fisher, G.A. Rodan, A.A. Reszka, Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins, Cell Death Differ. 11 (Suppl. 1) (2004) S108-118.
25. S. Menon, B.D. Manning, Common corruption of the mTOR signaling network in human tumors, Oncogene 27 (Suppl. 2) (2008) S43-51.
26. A. Ravaud, J.C. Bernhard, M. Gross-Goupil, L. Digue, J.M. Ferriere, mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma, Bull. Cancer 97 (2010) 45-51.
27. J. Baselga, V. Semiglazov, P. van Dam, A. Manikhas, M. Bellet, J. Mayordomo, M. Campone, E. Kubista, R. Greil, G. Bianchi, J. Steinseifer, B. Molloy, E. Tokaji, H. Gardner, P. Phillips, M. Stumm, H.A. Lane, J.M. Dixon, W. Jonat, H.S. Rugo, Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer, J. Clin. Oncol. 27 (2009) 2630-2637.
28. S.L. Ellard, M. Clemons, K.A. Gelmon, B. Norris, H. Kennecke, S. Chia, K. Pritchard, A. Eisen, T. Vandenberg, M. Taylor, E. Sauerbrei, M. Mishaeli, D. Huntsman, W. Walsh, M. Olivo, L. McIntosh, L. Seymour, Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163, J. Clin. Oncol. 27 (2009) 4536-4541.
29. A. Awada, F. Cardoso, C. Fontaine, L. Dirix, J. De Greve, C. Sotiriou, J. Steinseifer, C. Wouters, C. Tanaka, U. Zoellner, P. Tang, M. Piccart, The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics, Eur. J. Cancer 44 (2008) 84-91.
30. S. Chan, M.E. Scheulen, S. Johnston, K. Mross, F. Cardoso, C. Dittrich, W. Eiermann, D. Hess, R. Morant, V. Semiglazov, M. Borner, M. Salzberg, V. Ostapenko, H.J. Illiger, D. Behringer, N. Bardy-Bouxin, J. Boni, S. Kong, M. Cincotta, L. Moore, Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer, J. Clin. Oncol. 23 (2005) 5314-5322.
31. T. Okui, T. Shimo, T. Fukazawa, N. Kurio, N.M. Hassan, T. Honami, M. Takaoka, Y. Naomoto, A. Sasaki, Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction, Mol. Cancer Ther. 9 (2010) 2960-2969.
32. J.L. Fisher, R.J. Thomas-Mudge, J. Elliott, D.K. Hards, N.A. Sims, J. Slavin, T.J. Martin, M.T. Gillespie, Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically, Cancer Res. 66 (2006) 3620-3628.
33. J.T. Buijs, I. Que, C.W. Lowik, S.E. Papapoulos, G. van der Pluijm, Inhibition of bone resorption and growth of breast cancer in the bone microenvironment, Bone 44 (2009) 380-386.
34. B.A. Pulaski, S. Ostrand-Rosenberg, Mouse 4T1 Breast Tumor Model, in: Current Protocols in Immunology, John Wiley & Sons, Inc., 2001.
35. T. Hiraga, P.J. Williams, G.R. Mundy, T. Yoneda, The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases, Cancer Res. 61 (2001) 4418-4424.
36. R.J. Thomas, T.A. Guise, J.J. Yin, J. Elliott, N.J. Horwood, T.J. Martin, M.T. Gillespie, Breast cancer cells interact with osteoblasts to support osteoclast formation, Endocrinology 140 (1999) 4451-4458.
37. E. Corey, J.E. Quinn, F. Bladou, L.G. Brown, M.P. Roudier, J.M. Brown, K.R. Buhler, R.L. Vessella, Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells, Prostate 52 (2002) 20-33.
38. J.A. Kiefer, R.L. Vessella, J.E. Quinn, A.M. Odman, J. Zhang, E.T. Keller, P.J. Kostenuik, C.R. Dunstan, E. Corey, The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft, Clin. Exp. Metast. 21 (2004) 381-387.
39. D.I. Rosenthal, Radiologic diagnosis of bone metastases, Cancer 80 (1997) 1595-1607.
40. V. Vassiliou, C. Kalogeropoulou, T. Petsas, M. Leotsinidis, D. Kardamakis, Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between clinical status of patients and type of bone metastases?, Clin Exp. Metast. 24 (2007) 49-56.
41. J.E. Brown, R.J. Cook, A. Lipton, L. Costa, R.E. Coleman, Prognostic factors for skeletal complications from metastatic bone disease in breast cancer, Breast Cancer Res. Treat. 123 (2010) 767-779.
42. R.E. Coleman, P.J. Woll, M. Miles, W. Scrivener, R.D. Rubens, Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD), Br. J. Cancer 58 (1988) 621-625.
43. G.N. Hortobagyi, R.L. Theriault, L. Porter, D. Blayney, A. Lipton, C. Sinoff, H. Wheeler, J.F. Simeone, J. Seaman, R.D. Knight, Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group, N. Engl. J. Med. 335 (1996) 1785-1791.
44. U. Tateishi, C. Gamez, S. Dawood, H.W. Yeung, M. Cristofanilli, H.A. Macapinlac, Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT, Radiology 247 (2008) 189-196.
45. W.C. Noh, W.H. Mondesire, J. Peng, W. Jian, H. Zhang, J. Dong, G.B. Mills, M.C. Hung, F. Meric-Bernstam, Determinants of rapamycin sensitivity in breast cancer cells, Clin. Cancer Res. 10 (2004) 1013-1023.
46. Q. Zeng, Z. Yang, Y.J. Gao, H. Yuan, K. Cui, Y. Shi, H. Wang, X. Huang, S.T. Wong, Y. Wang, S. Kesari, R.R. Ji, X. Xu, Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study, Eur. J. Cancer 46 (2010) 1132-1143.
47. S.W. Wong, K.H. Tiong, W.Y. Kong, Y.C. Yue, C.H. Chua, J.Y. Lim, C.Y. Lee, S.I. Quah, C. Fow, C. Chung, I. So, B.S. Tan, H.L. Choo, R. Rosli, S.K. Cheong, C.O. Leong, Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73, Breast Cancer Res. Treat. (2010).
48. D. Cejka, S. Hayer, B. Niederreiter, W. Sieghart, T. Fuereder, J. Zwerina, G. Schett, Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis, Arthritis Rheum. 62 (2010) 2294-2302.
49. K. Araki, A.P. Turner, V.O. Shaffer, S. Gangappa, S.A. Keller, M.F. Bachmann, C.P. Larsen, R. Ahmed, mTOR regulates memory CD8 Tcell differentiation, Nature 460 (2009) 108-112.
50. M. Ohtani, S. Nagai, S. Kondo, S. Mizuno, K. Nakamura, M. Tanabe, T. Takeuchi, S. Matsuda, S. Koyasu, Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells, Blood 112 (2008) 635-643.
51. T. Welte, D. Leitenberg, B.N. Dittel, B.K. al-Ramadi, B. Xie, Y.E. Chin, C.A. Janeway Jr., A.L. Bothwell, K. Bottomly, X.Y. Fu, STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation, Science 283 (1999) 222-225.
52. Z. Yao, Y. Cui, W.T. Watford, J.H. Bream, K. Yamaoka, B.D. Hissong, D. Li, S.K. Durum, Q. Jiang, A. Bhandoola, L. Hennighausen, J.J. O'Shea, Stat5a/b are essential for normal lymphoid development and differentiation, Proc. Natl. Acad. Sci. USA 103 (2006) 1000-1005.
53. R. Moriggl, D.J. Topham, S. Teglund, V. Sexl, C. McKay, D. Wang, A. Hoffmeyer, J. van Deursen, M.Y. Sangster, K.D. Bunting, G.C. Grosveld, J.N. Ihle, Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells, Immunity 10 (1999) 249-259.
54. F. Pericle, R.A. Kirken, V. Bronte, G. Sconocchia, L. DaSilva, D.M. Segal, Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes, J. Immunol. 159 (1997) 2580-2585.
55. U.K. Singha, Y. Jiang, S. Yu, M. Luo, Y. Lu, J. Zhang, G. Xiao, Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells, J. Cell Biochem. 103 (2008) 434-446.
56. S.K. Martin, S. Fitter, L.F. Bong, J.J. Drew, S. Gronthos, P.R. Shepherd, A.C. Zannettino, NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells, J. Bone Miner. Res. 25 (2010) 2126-2137.